Jasemi Seyedesomaye, Molicotti Paola, Fais Milena, Cossu Ilaria, Simula Elena Rita, Sechi Leonardo A
Department of Biomedical Sciences, Division of Microbiology and Virology, University of Sassari, 07100 Sassari, Italy.
Struttura Complessa Microbiologia e Virologia, Azienda Ospedaliera Universitaria Sassari, 07100 Sassari, Italy.
Toxins (Basel). 2025 Jun 16;17(6):305. doi: 10.3390/toxins17060305.
Enterotoxigenic (ETBF) has emerged as a gut microbiome pathogen that can promote intestinal inflammation and contribute to colorectal cancer (CRC). Its principal virulence factor, the toxin (BFT), is a zinc-dependent metalloprotease that disrupts epithelial barrier integrity, initiates inflammatory signaling pathways, and enhances epithelial proliferation. Although growing evidence supports a link between ETBF and CRC, some inconsistencies across studies highlight the need for further investigation into the molecular mechanisms underpinning BFT-mediated pathogenesis. This review examines the biological structure and activity of BFT, with a focus on its role in epithelial injury, inflammatory responses, and tumorigenesis. In addition, we discuss current challenges in the detection and characterization of ETBF and BFT, including technical limitations in clinical diagnostics and methodological variability across studies. Recent advances in multi-omics technologies, molecular diagnostics, nanobody-based detection platforms, and probiotic intervention are also highlighted as promising avenues for improving ETBF identification and therapeutic targeting. Future research integrating systematic molecular profiling with clinical data is essential to enhance diagnostic accuracy, elucidate pathophysiological mechanisms, and develop effective interventions against ETBF-associated diseases.
产肠毒素脆弱拟杆菌(ETBF)已成为一种肠道微生物群病原体,可促进肠道炎症并导致结直肠癌(CRC)。其主要毒力因子毒素(BFT)是一种锌依赖性金属蛋白酶,可破坏上皮屏障完整性,启动炎症信号通路,并增强上皮细胞增殖。尽管越来越多的证据支持ETBF与CRC之间存在联系,但各研究之间的一些不一致之处凸显了进一步研究BFT介导的发病机制的分子机制的必要性。本综述探讨了BFT的生物学结构和活性,重点关注其在上皮损伤、炎症反应和肿瘤发生中的作用。此外,我们讨论了ETBF和BFT检测与表征方面的当前挑战,包括临床诊断中的技术限制以及各研究之间的方法学差异。多组学技术、分子诊断、基于纳米抗体的检测平台和益生菌干预方面的最新进展也被强调为改善ETBF鉴定和治疗靶点的有前景的途径。将系统分子谱分析与临床数据相结合的未来研究对于提高诊断准确性、阐明病理生理机制以及开发针对ETBF相关疾病的有效干预措施至关重要。